367 related articles for article (PubMed ID: 25359333)
1. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
[No Abstract] [Full Text] [Related]
2. Bedaquiline: finding the pores on the pot.
Salfinger M; Migliori GB
Eur Respir J; 2015 Jul; 46(1):289-91. PubMed ID: 26130783
[No Abstract] [Full Text] [Related]
3. Bedaquiline: finding the pores on the pot.
Mohapatra PR
Eur Respir J; 2015 Jul; 46(1):288-9. PubMed ID: 26130782
[No Abstract] [Full Text] [Related]
4. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending.
Salfinger M; Migliori GB
Eur Respir J; 2015 Feb; 45(2):317-21. PubMed ID: 25653264
[No Abstract] [Full Text] [Related]
5. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
6. Clofazimine Exposure
Ismail N; Peters RPH; Ismail NA; Omar SV
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642938
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
8. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
[TBL] [Abstract][Full Text] [Related]
9. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
[TBL] [Abstract][Full Text] [Related]
10. Daily Dosing for Bedaquiline in Patients with Tuberculosis.
Salinger DH; Nedelman JR; Mendel C; Spigelman M; Hermann DJ
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451504
[TBL] [Abstract][Full Text] [Related]
11. Sub-MIC levels of bedaquiline and clofazimine can select
Villellas C; Stevenaert F; Remmerie B; Andries K
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.
Ghodousi A; Rizvi AH; Baloch AQ; Ghafoor A; Khanzada FM; Qadir M; Borroni E; Trovato A; Tahseen S; Cirillo DM
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262765
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
[TBL] [Abstract][Full Text] [Related]
14. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
[TBL] [Abstract][Full Text] [Related]
15. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.
Ismail N; Omar SV; Ismail NA; Peters RPH
J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087
[TBL] [Abstract][Full Text] [Related]
16. Clofazimine in the treatment of multidrug-resistant tuberculosis.
Xu HB; Jiang RH; Xiao HP
Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
[TBL] [Abstract][Full Text] [Related]
17. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E
Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800
[TBL] [Abstract][Full Text] [Related]
18. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M
Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
Maartens G; Brill MJE; Pandie M; Svensson EM
Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
[TBL] [Abstract][Full Text] [Related]
20. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
